Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan

On June 21, the strategic investment press conference of Createrna was held at the Biolake, Donghu New & High Technology Development Zone, Wuhan. During the event, Createrna signed a cooperation agreement with Lilly Asia Ventures (LAV), marking its completion of Series A financing to enter the capital market, a move that brings it one step closer to an IPO.

(LAV and Createrna signing cooperation agreement)

Createrna also unveiled its future strategic plans through three dimensions. It outlined its commitment to an innovative R&D strategy that emphasizes simultaneous advancement in pipeline development and platform construction, a "going global" strategy that focuses on the operation of intellectual property rights and the integration of international resources, and a capitalization strategy that encourages active engagement in both domestic and international capital markets, all aiming to drive itself towards becoming a research-oriented enterprise that is globally recognized.

About Lilly Asia Ventures

Lilly Asia Ventures (LAV) is one of the pioneering biomedical-focused funds that began operating in China. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, LAV spun off and became an independent investment management company. Now, it has developed into a leading venture capital fund in the life sciences and healthcare sector. Building an extensive presence in the Chinese market, LAV has been continuously investing in the healthcare industry, with a particular focus on and rich experience in preclinical and clinical development, regulatory policies, and commercial markets. Guided by a "people-first" investment philosophy, LAV remains dedicated to product-oriented investments, prioritizing reliable scientific technologies. Its vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.

About Createrna

Founded in 2013, Createrna is a high-tech enterprise specializing in innovative drug R&D, production, and operation. Following a R&D strategy developing drugs with unique and more advanced/favorable characteristics to address the unmet medical  needs, Createrna’s pipelines cover several treatment areas including cardiovascular system, respiratory system, autoimmune disorders, pain, and kidney diseases. Createrna currently encompass over 20 pipelines at different drug development stages. Notably, eight pipelines have progressed to clinical stages from Phase 1 to Phase 3. Another four are in preclinical stage of drug development.The goal of Createrna is to emerge as a globally competitive, top-tier innovative pharmaceutical company in the specialized field.